ESSA Pharma Inc (NASDAQ:EPIX)( TSX-V:EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, has reported its financial results for the fiscal first quarter ended 31 December 2019, it was reported on Thursday.

The company reported net loss of USD4.6m for the quarter ended 31 December 2019, compared to a net loss of USD2.7m in the year-ago period.

The firm posted general and administration expenditures of USD2.1m in the quarter ended 31 December 2019, compared to USD1.2m in the same period in 2018.

David Parkinson, ESSA MD, president and CEO, stated, 'This past calendar year was a transformative year for ESSA, and we are excited to continue the momentum into 2020. Preparations for an IND filing are nearly complete and we remain on track to file the IND in the first quarter of 2020 with an initiation of the Phase 1 study of EPI-7386 expected shortly thereafter.'